$ADMS FDA Approval of GOCOVRI™ for Dyskinesia in Parkinson’s

Conference call and webcast scheduled for today at 4:30 pm ET

EMERYVILLE, Calif., Aug. 24, 2017 – Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved GOCOVRI (amantadine) extended release capsules (previously ADS-5102) for treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI, previously granted orphan drug status by the FDA, is the first and only medicine approved by the FDA for this indication.

“GOCOVRI’s approval is an important advancement for the treatment of Parkinson’s disease, as it is the first FDA-approved medicine for the treatment of dyskinesia in Parkinson’s disease patients,” said Rajesh Pahwa, M.D., Laverne & Joyce Rider Professor of Neurology at the Kansas Medical Center and Director, Parkinson’s Disease Center of Excellence at the University of Kansas Health System. “Notably, GOCOVRI is the first Parkinson’s disease medicine proven in controlled trials to reduce both dyskinesia and OFF time in Parkinson’s disease patients receiving levodopa. Treatment of dyskinesia and OFF time continues to be an unmet need in the medical management of Parkinson’s disease and the approval of GOCOVRI is a major step in that direction.”

GOCOVRI is a high dose 274 mg amantadine (equivalent to 340 mg amantadine HCl) taken once-daily at bedtime that delivers consistently high levels of amantadine from the morning and throughout the day when dyskinesia occurs. Dyskinesia is a consequence of levodopa-based Parkinson’s disease treatment and is characterized by involuntary and non-rhythmic movements that are purposeless and unpredictable, which impact the activities of daily living.

“Dyskinesia can significantly compromise quality of life for people with Parkinson’s disease,” said Dr. Todd Sherer, Chief Executive Officer of The Michael J. Fox Foundation for Parkinson’s Research. “We are pleased that patients have another option to manage this aspect of the disease and glad the Unified Dyskinesia Rating Scale – a tool our support helped develop and validate – could show clinical efficacy of GOCOVRI for the treatment of dyskinesia.”

GOCOVRI’s positive benefit/safety profile was established in two Phase 3 controlled clinical trials in Parkinson’s disease patients with dyskinesia. In Study 1, patients treated with GOCOVRI demonstrated statistically significant and clinically relevant reductions in dyskinesia, with a 37 percent reduction in Unified Dyskinesia Rating Scale (UDysRS) total score vs. 12 percent for placebo at Week 12. These results were confirmed in Study 2 in which GOCOVRI achieved a 46 percent reduction in UDysRS vs. 16 percent for placebo. Additionally, key secondary data from Parkinson’s disease patient reported diaries in Study 1 and Study 2 respectively, showed that GOCOVRI-treated patients experienced a 3.6 and 4.0 hour increase in functional time daily (defined as ON time without troublesome dyskinesia) vs. a 0.8 and 2.1 hour increase for placebo-treated patients at Week 12. The increases in functional time were achieved by decreases in both ON time with troublesome dyskinesia and OFF time. The placebo-adjusted reduction in OFF time in both studies was approximately 1 hour per day. The most commonly observed adverse reactions (>10 percent and greater than placebo) with GOCOVRI were hallucinations, dizziness, dry mouth, peripheral edema, constipation, fall and orthostatic hypotension. For additional Important Safety Information, see below.

“Today’s approval is a tremendous milestone for Adamas and for the Parkinson’s disease community,” said Gregory T. Went, Ph.D., Founder, Chairman and Chief Executive Officer of Adamas Pharmaceuticals, Inc. “GOCOVRI has the potential to help people with Parkinson’s disease suffering from dyskinesia by finally providing physicians with an effective tool to address this long-standing unmet medical need. We thank the physicians, clinical staff, patients and their families who participated in the clinical trials for making this advancement possible for the community.”

GOCOVRI is expected to be available in the fourth quarter, and formally launched with the full deployment of Adamas’s sales force in January 2018. Adamas developed GOCOVRI for people with Parkinson’s disease and the company is committed to helping them gain access. Adamas has created “GOCOVRI Onboard,” a patient services program, which will facilitate access and distribution. “GOCOVRI Onboard” will work with patients, their families and physicians to obtain access to GOCOVRI via reimbursement support, prescription fulfillment and financial assistance. “GOCOVRI Onboard” is designed to deliver dedicated assistance and financial support to patients in need.

Investor Conference Call and Webcast
Adamas will host a conference call and webcast today, August 24, 2017, at 4:30 p.m. Eastern Time. The conference call may be accessed by dialing 844-215-3280 for participants in the U.S. or Canada and 484-747-6383 for international callers. The webcast can be accessed live via the investor section of the Adamas website at http://ir.adamaspharma.com/events.cfm and will be available for replay until September 24, 2017.

About Parkinson’s Disease and Dyskinesia
Parkinson’s disease is a chronic neurodegenerative disorder affecting close to one million people in the U.S. Parkinson’s disease results from a loss of dopamine in the brain and is commonly treated by levodopa and dopaminergic therapies that help replace lost dopamine. As the disease progresses, people require increasingly higher or more frequent doses of levodopa in order to avoid the recurrent periods of OFF time – characterized by slowness of movement, rigidity, impaired walking, tremor and postural instability – when the underlying symptoms of Parkinson’s disease return.

Over time, nearly 90 percent of people on levodopa therapy experience dyskinesia, which is characterized by involuntary and non-rhythmic movements during waking hours that are purposeless and unpredictable. Dyskinesia can interfere with people’s daily living, resulting in functional impairment and disability. People with Parkinson’s disease often experience multiple fluctuating periods of OFF time and dyskinesia during any given day, which can impede their movement and daily function. In the U.S., there are approximately 150,000 – 200,000 people with Parkinson’s disease whose daily life is impacted by dyskinesia. Until now, physicians have had limited options to manage, and have had no approved medicines to treat dyskinesia.

About GOCOVRI
GOCOVRI is the first and only medicine approved by the FDA for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI is a high-dose 274 mg amantadine taken once-daily at bedtime, which delivers consistently high levels of amantadine in the morning and throughout the day when dyskinesia is most prevalent. GOCOVRI has received orphan drug status from the FDA. For more information about GOCOVRI, including the full Prescribing Information, please call 1-844-GOCOVRI [1-844-462-6874] or visit www.GOCOVRI.com.

About Adamas Pharmaceuticals, Inc.
At Adamas, we believe in the power and the promise of medicines derived from a deep understanding of time-dependent biology. Our expertise lies in uncovering and mapping the relationship between disease and drug activity. From there, we strive to create medicines with therapeutic profiles that match the pattern of disease to drive a more significant and durable clinical effect. This understanding of time-dependent biological processes informs our every innovation, targeting advancement in treatment of chronic neurologic disorders. Our portfolio includes: GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; ADS-5102 in development for the treatment of multiple sclerosis walking impairment and additional indications in Parkinson’s disease, and ADS-4101, a high-dose, modified-release lacosamide in Phase 1 clinical development for the treatment of partial onset seizures in patients with epilepsy. Additionally, Adamas’s licensed assets are currently marketed by Allergan under the brand names NAMENDA XR^® and NAMZARIC^®, and Adamas is eligible to receive royalties on sales of these medicines beginning in June 2018 and May 2020, respectively. For more information, please visit www.adamaspharma.com.

NAMENDA XR^® and NAMZARIC^® are trademarks of Merz Pharma GmbH & Co. KGaA.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
GOCOVRI ^TM is contraindicated in patients with creatinine clearance below 15 mL/min/1.73 m².

WARNINGS AND PRECAUTIONS
Falling Asleep During Activities of Daily Living and Somnolence: Patients treated with Parkinson’s disease medications have reported falling asleep during activities of daily living. If a patient develops daytime sleepiness during activities that require full attention (e.g., driving a motor vehicle, conversations, eating), GOCOVRI should ordinarily be discontinued or the patient should be advised to avoid potentially dangerous activities.
Suicidality and Depression: Monitor patients for depression, including suicidal ideation or behavior. Prescribers should consider whether the benefits outweigh the risks of treatment with GOCOVRI in patients with a history of suicidality or depression.
Hallucinations/Psychotic Behavior: Patients with a major psychotic disorder should ordinarily not be treated with GOCOVRI because of the risk of exacerbating psychosis. Observe patients for the occurrence of hallucinations throughout treatment, especially at initiation and after dose increases.
Dizziness and Orthostatic Hypotension: Monitor patients for dizziness and orthostatic hypotension, especially after starting GOCOVRI or increasing the dose.
Withdrawal-Emergent Hyperpyrexia and Confusion: Rapid dose reduction or abrupt discontinuation of GOCOVRI, may cause an increase in the symptoms of Parkinson’s disease or cause delirium, agitation, delusions, hallucinations, paranoid reaction, stupor, anxiety, depression, or slurred speech.  Avoid sudden discontinuation of GOCOVRI.
Impulse Control/Compulsive Behaviors: Patients may experience urges (e.g., gambling, sexual, money spending, binge eating) and the inability to control them. It is important for prescribers to ask patients or their caregivers about the development of new or increased urges. Consider dose reduction or stopping medications.

ADVERSE REACTIONS
The most common adverse reactions (>10%) were hallucination, dizziness, dry mouth, peripheral edema, constipation, fall, and orthostatic hypotension.

DRUG INTERACTIONS
Other Anticholinergic Drugs: The dose of GOCOVRI should be reduced if atropine-like effects are observed.
Drugs Affecting Urinary pH: The pH of the urine has been reported to influence the excretion rate of amantadine. Monitor for efficacy or adverse reactions under conditions that alter the urine pH.
Alcohol: Concomitant use with alcohol is not recommended, as it may increase the potential for CNS effects such as dizziness, confusion, lightheadedness, and orthostatic hypotension.

Forward-looking Statements
Statements contained in this press release regarding expected future events are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements contained in this press release regarding the expected benefits of GOCOVRI,  physician and patient access in fourth quarter 2017 and launch of GOCOVRI (amantadine) extended release capsules (previously ADS-5102) in January 2018 for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and Adamas’ plans to offer a number of programs providing patient access support throughout the course of treatment, along with commercial copay assistance and financial assistance for patients who are uninsured or underinsured.  Words such as “potentially,” “expected,” “will,” “plans” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. For a description of risks and uncertainties that could cause actual results to differ from those expressed in forward-looking statements, including risks relating to Adamas’ research, clinical, development, and commercial activities relating to ADS-5102 and ADS-4101, and the regulatory and competitive environment and Adamas’ business in general, see Adamas’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2017. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Adamas undertakes no obligation to update any forward-looking statement in this press release.

Contact:

Investor 
Ashleigh Barreto
Director, Corporate Communications & Investor Relations
Adamas Pharmaceuticals, Inc.
510-450-3567
ir@adamaspharma.com

Media
Kelley Kaufman
inVentiv Health
805-637-2491
Kelley.Kaufman@inventivhealth.com

$CDNA Confirms AlloSure Will Receive Medicare Coverage Effective October 9th, 2017

Precision Medicine for Kidney Transplant Patients is here

BRISBANE, Calif., Aug. 24, 2017 — CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that AlloSure qualifies for Medicare coverage effective October 9th, 2017.

The Centers for Medicare and Medicaid Services (CMS) released the final version of the coverage policy issued by Palmetto GBA, the Medicare administrator responsible for the MolDX technology assessment program that evaluated AlloSure.

“This is the moment we have all been preparing for, CareDx is ready to begin offering AlloSure to transplant centers across the US, ahead of our original timeline. We are hearing great interest from transplant nephrologists who want to begin using AlloSure as soon as CMS approval is finalized,” said Peter Maag, Chief Executive Officer. “We see the coverage decision by the MolDX team as a great signal for the support of kidney transplant patients and an acknowledgement of the unmet medical need. About 80% of kidney transplant patients are covered by Medicare, so many patients will have access to AlloSure, a new milestone in precision medicine in transplantation.”

About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure™ for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA testing.

For more information, please visit: www.CareDx.com.

Forward Looking Statements
This press release contains forward-looking statements about our business, research, development and commercialization efforts including, but not limited to the development, commercialization, utility, performance and adoption of AlloSure. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risk associated with successful research, development and planned commercialization of our technologies, that are described in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2015 filed by us with the SEC on March 29, 2016 and the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2016 filed by us with the SEC on November 14, 2016.  Any of these may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

Contact
Sasha King, Chief Commercial Officer
T: +1 415-287-2393
E: sking@caredx.com

$XXII Tobacco #Smoking Harm Reduction Tech a Potential “Game Changer”

CLARENCE, N.Y.

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, announced today that a growing number of independent scientists specializing in tobacco harm reduction are publicly proclaiming that the FDA’s recently announced plan to reduce nicotine to non-addictive levels in cigarettes will drastically improve public health. Noted experts have proclaimed that Very Low Nicotine cigarettes will “end the combustible tobacco epidemic” and “could save more lives than any other act of a governmental agency in all of human history.”

Dr. Neal Benowitz, a tobacco science expert and a professor at the University of California, San Francisco School of Medicine, wrote an article published on August 15, 2017 in the Annals of Internal Medicine entitled “Comprehensive Nicotine Regulation to End the Combustible Tobacco Epidemic.” In the perspective article, Dr. Benowitz states that an FDA-mandated 95% reduction in nicotine content would “make it impossible to compensate by smoking cigarettes more intensively or smoking more per day.” Like many other health experts, Dr. Benowitz recognizes that compensatory smoking does not occur when the nicotine content of combustible cigarettes is reduced by 95% as compared to conventional cigarettes. 22nd Century is the only company in the world that is capable of growing tobacco with nicotine levels of just 0.4mg per gram of tobacco – a 95% reduction in nicotine.

The vast majority of public health advocates, tobacco control experts, and scientists have widely embraced the FDA’s proposed nicotine policy. In fact, outside of “Big Tobacco” companies, few critics of the nicotine reduction plan have emerged and the FDA has now strongly affirmed its regulatory authority for cigarette product standards. On August 16, 2017, Scott Gottlieb, M.D., the Commissioner of the FDA and Mitchell Zeller, J.D., the Director of FDA’s Center for Tobacco Products, released an article entitled, “A Nicotine-Focused Framework of Public Health.” Published in The New England Journal of Medicine (NEJM), the article spells out the FDA’s regulatory authority for mandating non-addictive levels of nicotine in combustible cigarettes. Gottlieb and Zeller point to the 2009 Tobacco Control Act that authorizes the FDA to establish tobacco product standards that are appropriate for the protection of public health. The NEJM article states, the agency has “clear authority” [emphasis added] to reduce nicotine levels. On the issue of compensatory smoking, the authors state that, “FDA will be led by the science” and they reference several independent clinical studies that suggest minimum compensation when smokers use 22nd Century’s proprietary Very Low Nicotine research cigarettes. Gottlieb and Zeller reference a recent 6-week study by Donny, et al. that showed that “cigarettes with lower nicotine content reduced nicotine exposure and dependence, as well as the number of cigarettes smoked, as compared with cigarettes with standard nicotine levels.” [emphasis added]

In their concluding paragraph, Commissioner Gottlieb and Director Zeller highlight the ultimate goal of a nicotine mandate: “The public health benefits of implementing a nicotine-reduction policy for combustible cigarettes could be enormous: we would expect smoking-related morbidity and premature mortality to decrease considerably.”

Dr. Benowitz, Commissioner Gottlieb and Director Zeller are not alone in their determination to regulate nicotine. In a May 2017 survey conducted by Harris Poll online, 68% of more than 2,000 adults across the United States voiced support for government to mandate that all cigarettes have very low, non-addictive levels of nicotine. A similar percentage of surveyed adults in Japan (73%), Australia (77%), Canada (76%) and the United Kingdom (76%) also agreed that their governments should mandate very low, non-addictive levels of nicotine for cigarettes.

On August 22, 2017, Stanford professor, Robert N. Proctor, Ph.D., authored an editorial published in Tobacco Control entitled, “FDA’s new plan to reduce the nicotine in cigarettes to sub-addictive levels could be a game-changer.” Professor Proctor reasons that limiting cigarettes to non-addictive levels of nicotine is a moral imperative when he asserts: “Smokers would be able to start or quit at will, without suffering the robbery of choice that defines addiction.” The Tobacco Control editorial argues, convincingly, that the new FDA plan “could save more lives than any other act of a government agency in all of human history. The magnitude of the harms is that great. We hear a lot about tobacco endgames: this one could be a game-changer.” [emphasis added]

In recognition and acceptance of this inevitable, upcoming paradigm shift in the combustible tobacco market, the Chief Executive Officer of Philip Morris International (PMI), Andre Calatzopoulos, stated in an article published by Reuters on August 22, 2017 and entitled “Philip Morris International CEO Cheers U.S. FDA Tobacco Proposal,” that PMI was actually “extremely encouraged” by the FDA’s recent proposal to lower nicotine levels in cigarettes and called it “one of the best articulated positions in many years” that does not require “litigation or anything of this nature.”

“More than $100 Million of independent research has demonstrated that 22nd Century’s proprietary Very Low Nicotine tobacco could save many millions of lives and will prevent future generations of young people from becoming addicted to cigarettes,” explained Henry Sicignano, III, President and Chief Executive Officer of 22nd Century Group. “22nd Century’s technology is proven. The FDA plan is already feasible. The time to implement a mandate of Very Low Nicotine tobacco in all combustible cigarettes sold in the United States has arrived.”

About 22nd Century Group, Inc.

22nd Century is a plant biotechnology company focused on genetic engineering and plant breeding which allows the increase or decrease of the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants. The Company’s primary mission in tobacco is to reduce the harm caused by smoking. The Company’s primary mission in cannabis is to develop proprietary hemp/cannabis strains for important new medicines and agricultural crops. Visit www.xxiicentury.com and www.botanicalgenetics.com for more information.

Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking information, including all statements that are not statements of historical fact regarding the intent, belief or current expectations of 22nd Century Group, Inc., its directors or its officers with respect to the contents of this press release, including but not limited to our future revenue expectations. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances, or to reflect the occurrence of unanticipated events. You should carefully review and consider the various disclosures made by us in our annual report on Form 10-K for the fiscal year ended December 31, 2016, filed on March 8, 2017, including the section entitled “Risk Factors,” and our other reports filed with the U.S. Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.

$MRAM Appoints Semiconductor Storage Veteran Kevin Conley as CEO

CHANDLER, Ariz., Aug. 23, 2017  — Everspin Technologies, Inc. (Nasdaq:MRAM), the world’s leading developer and manufacturer of Magnetoresistive Random Access Memory (MRAM), today announced it had named Kevin Conley as its President and Chief Executive Officer effective Sept. 1. Conley succeeds Phill LoPresti as the company moves aggressively to capitalize on Storage Class Memory opportunities with its MRAM technology leadership.

“Kevin’s experience building high-growth technology businesses, including a market leading SSD business at Flash memory pioneer SanDisk, makes him an ideal selection to fulfill Everspin’s vision of making high-endurance, fast, and persistent MRAM ubiquitous in computing applications,” said Everspin lead Board Director Geoff Tate.

Conley joined Everspin’s Board of Directors in March of 2017 and has been active with the company in refining its strategy. Prior to that, Conley was Senior Vice President and Chief Technology Officer of SanDisk until June 2016, where he was focused on fostering strategic innovation at the company. Previously, he served as Senior Vice President and General Manager of SanDisk’s Client Storage Solutions business unit that he built from the ground up to over $1 billion in annual revenue. As Vice President of Engineering at Corsair, he transformed and expanded the product portfolio to grow the company to a leader in PC gaming components, including high performance SSDs. Prior to Corsair, Conley spent over 15 years at SanDisk, holding several key system engineering leadership positions developing leadership non-volatile memory products. He is listed as the inventor or co-inventor on over 80 patents in the area of non-volatile memory architecture and management.

“From wearables to self-driving cars to big data analytics in the data center, there is an insatiable appetite developing for low latency high endurance non-volatile memory,” said incoming Everspin CEO Kevin Conley. “Everspin has been a MRAM technology pioneer and its Spin-Torque MRAM (ST-MRAM) holds the potential to address this market and disrupt the traditional computational memory hierarchy. I am grateful for the exciting opportunity to lead this talented team.”

“It has been an honor to work alongside the industry’s most successful MRAM team as well as with our incredible customers, partners and investors for the past seven years. I am confident Kevin’s experience will help Everspin achieve its fullest potential and I look forward to working closely with him to help ensure a smooth transition,” said Everspin’s CEO Phill LoPresti.

LoPresti will step down as CEO and from the Everspin Board of Directors, effective August 31, 2017, but will remain an advisor for the following six months. “We appreciate Phill LoPresti’s seven years of leadership, guiding Everspin through a period of continued growth and through a NASDAQ IPO last year,” said Tate. “We wish him well in his future endeavors.”

About Everspin

Everspin Technologies is the leading provider of Magnetoresistive RAM (MRAM) solutions.  Everspin’s MRAM solutions enable the protection of mission critical data by combining the persistence of non-volatile memory with the speed and endurance of SRAM or DRAM.  Everspin’s MRAM solutions allow its customers in the industrial, automotive, and enterprise storage markets to design high performance and reliable systems. Everspin is the only provider of commercially available MRAM solutions and has shipped over 70 million MRAM units. For more information, visit www.everspin.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding future events that involve risks and uncertainties that could cause actual results or events to differ materially from the expectations disclosed in the forward-looking statement, including, but not limited to: the market may not adopt Everspin’s products and technology at the rate Everspin expects; the ability for Everspin to expand the markets Everspin addresses at the rate it expects; the risk that unexpected technical difficulties may develop in the final stages of development or production of its products; and the risk that the integration of the CEO into his new role will take longer than expected. Readers are advised that they should not place undue reliance on these forward-looking statements and should review the risk factors included in Everspin’s various filings with the Securities and Exchange Commission, including, but not limited to, in its Quarterly Report on Form 10-Q filed with the SEC on August 11, 2017, Annual Report on Form 10K filed with the SEC on March 29, 2017, under the caption “Risk Factors Related to Our Business and Our Industry.” Subsequent events may cause these expectations to change, and Everspin disclaims any obligations to update or alter these forward-looking statements in the future, whether as a result of new information, future events or otherwise.

Everspin Investor Contact:

David H. Allen
408-427-4463
DAllen@DarrowIR.com

$SRTS to Present at the 6th Annual Liolios Gateway Conference on Sept 6

BOCA RATON, Fla., Aug. 23, 2017 — Sensus Healthcare, Inc. (Nasdaq:SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), has been invited to present at the 2017 Gateway Conference, which is being held on September 6-7, 2017 at the Four Seasons Hotel San Francisco.

Joseph Sardano, President and CEO of Sensus Healthcare, is scheduled to present on Wednesday, September 6 at 11:30 a.m. Pacific time, with one-on-one meetings held throughout the conference.

The presentation will be webcast live and available for replay in the Investor Relations section of the Company’s website at sensushealthcare.com or on the Gateway Conference website at www.gateway-conference.com/presenters.

To receive additional information, request an invitation or to schedule a one-on-one meeting, please email gateway@liolios.com.

About the Gateway Conference

The 6^th Annual Gateway Conference is an invite-only conference presented by Liolios, which brings together the most compelling companies with the nation’s top institutional investors and analysts. This year’s event features more than 100 companies from a number of growth industries, including technology, business and financial services, consumer, digital media, clean technology and life sciences. The format has been designed to give attendees direct access to senior management via company presentations, Q&A sessions and one-on-one meetings. For more information, visit www.gateway-conference.com or www.liolios.com.

About Sensus Healthcare

Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit http://www.sensushealthcare.com.

Contact:
LHA Investor Relations 
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com

$ITCI Positive Regulatory Update On #Schizophrenia Program

Following FDA interactions Company moving forward with long-term safety study of lumateperone and preparing for NDA submission for the treatment of schizophrenia by mid-2018

NEW YORK, Aug. 23, 2017 — Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that the FDA (i) has completed its review of the Company’s responses to requests from the FDA for additional information relating to certain findings observed in nonclinical toxicology studies of lumateperone in an animal species and (ii) agrees that the Company has presented adequate data to support its position that the metabolic pathway in the animal species is distinctive from humans, which indicates that the toxicity observed in the animal species is not relevant to humans.

Accordingly, the Company is moving forward with its long-term safety study of lumateperone and intends to submit a new drug application (NDA) for the treatment of schizophrenia by mid-2018.

The Company previously announced that the FDA had raised questions relating to certain findings observed in nonclinical toxicology studies of lumateperone in an animal species and requested additional information to confirm that the nonclinical findings are not indicative of a safety risk associated with long term exposure in humans.  The data presented by the Company supports the position that there are significant species differences in the metabolism of lumateperone.  Based on the FDA’s agreement that the Company presented adequate data indicating that the toxicity seen in the animal species is not relevant to humans, the Company is proceeding with its long-term safety study of lumateperone in patients with schizophrenia.  Further, based on feedback from the FDA, the Company will incorporate additional monitoring in its long-term safety study for metabolites seen in animal species but not seen to date in humans, and also will continue to monitor for toxicities in its nonclinical studies.  With over 1,500 people exposed to date, lumateperone has been well-tolerated with a safety profile similar to placebo.

“We are very pleased with the outcome of our discussions with the FDA and look forward to progressing our schizophrenia program,” said Dr. Sharon Mates, Chairman and CEO of ITCI.

The Company previously announced that it had requested guidance from the FDA on the acceptability of the two positive well-controlled clinical trials it has conducted (Study ITI-007-005 and Study ITI-007-301), with supportive evidence from Study ITI-007-302, as the basis for the submission of an NDA for the treatment of schizophrenia.  As previously disclosed, the FDA has confirmed that the results of Study ITI-007-302 do not preclude the Company from submitting an NDA based on the efficacy studies it has conducted to date and the Company intends to submit an NDA for lumateperone for the treatment of schizophrenia supported by the efficacy studies it has conducted to date.  Efficacy is supported by two positive large, randomized, double-blind, placebo-controlled US-based clinical studies at a fixed dose of lumateperone (ITI-007 60 mg) with no dose titration required. Across all three short-term efficacy studies the magnitude and trajectory of improvement with ITI-007 60 mg was similar. Additionally, supportive data provide evidence of pharmacological activity and clinical benefit of ITI-007 40 mg. Moreover, lumateperone has been well-tolerated, with a safety profile similar to placebo across all clinical studies conducted to date, and with clinically relevant and statistically significant safety and tolerability advantages when directly compared in two studies with risperidone used as an active control, the most commonly prescribed antipsychotic for the treatment of schizophrenia. These advantages include no significant adverse effects on cardiovascular parameters, weight, lipids, glucose, prolactin and motor function. Given the safety and tolerability limitations of existing antipsychotics (e.g., cardiovascular abnormalities, metabolic dysregulation and motor disturbances), the Company believes lumateperone, if approved, will be an attractive treatment option for physicians and their patients with schizophrenia.

To address long term safety and to observe the impact of switching from standard-of-care antipsychotic medications, the Company is conducting an open-label safety study in stable patients with schizophrenia switched to lumateperone (ITI-007 60 mg) from standard of care antipsychotic therapy. This study is being conducted in two parts. The first part has completed clinical conduct and included a 6-week treatment duration with lumateperone followed by a 2-week period where patients are switched back to standard-of-care. This study assesses both the impact of switching to lumateperone from standard-of-care antipsychotics as well as the impact of switching back to standard-of-care antipsychotics from lumateperone. Topline data from the first part of the study will be available shortly. The second part of the study, the Company’s long-term safety study in schizophrenia, is enrolling additional patients for up to 1 year treatment duration.

About Intra-Cellular Therapies

Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson’s and Alzheimer’s disease. The Company is developing its lead drug candidate, lumateperone (also known as ITI-007), for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, including Alzheimer’s disease, depression and other neuropsychiatric and neurological disorders. Lumateperone, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression and agitation associated with dementia, including Alzheimer’s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead molecule in the Company’s PDE1 portfolio, ITI-214 is in development for the treatment of symptoms associated with Parkinson’s disease.

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, our beliefs about the extent to which the results of our clinical trials to date support an NDA filing for lumateperone for the treatment of schizophrenia; our expectations regarding our timelines for submitting an NDA to the FDA for the treatment of schizophrenia; our belief that the toxicity findings observed in nonclinical animal toxicology studies of lumateperone are not indicative of a safety risk for humans; our belief that our monitoring in our ongoing long-term safety study and nonclinical studies will not impact our timelines for filing an NDA for lumateperone for the treatment of schizophrenia; our belief that lumateperone, if approved, will be an attractive treatment option for schizophrenia; and development efforts and plans under the caption “About Intra-Cellular Therapies.” All such forward-looking statements are based on management’s present expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include but are not limited to the following: any toxicities discovered in our long-term safety study of lumateperone in patients with schizophrenia and nonclinical studies could delay or prevent our filing of an NDA; the FDA may place our long-term safety study on a clinical hold, which would delay or prevent us from completing the safety study and from filing an NDA; our current and planned clinical trials, other studies for lumateperone, and our other product candidates may not be successful or may take longer and be more costly than anticipated; product candidates that appeared promising in earlier research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials; our proposals with respect to the regulatory path for our product candidates may not be acceptable to the FDA; our reliance on collaborative partners and other third parties for development of our product candidates; and the other risk factors detailed in our public filings with the Securities and Exchange Commission.  All statements contained in this press release are made only as of the date of this press release, and we do not intend to update this information unless required by law.

Contact:

Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D. 
Vice President, Corporate Communications and Investor Relations
646-440-9333

Burns McClellan, Inc.
Lisa Burns 
Justin Jackson (Media)
jjackson@burnsmc.com
212-213-0006

$RDNT Completion of Amendment to 1st Lein Facilities, Retirement of 2nd Lein Term Loan

LOS ANGELES, Aug. 22, 2017  — RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, fixed-site outpatient diagnostic imaging services through a network of 298 owned and/or operated outpatient imaging centers, today announced the successful closing of the previously announced efforts to amend (the “Amendment”) its senior secured first lien credit agreement to raise an additional $170,000,000 of senior secured first lien term loans, the proceeds of which were used to repay and retire RadNet’s second lien term loan.

After the issuance of the additional first lien term loans described above, RadNet’s senior secured first lien credit facilities consist of an aggregate of $637 million of first lien term loans and a $117.5 million senior secured revolving credit facility, which was undrawn as of June 30, 2017.  The first lien term loans have a maturity date of July 1, 2023 and the revolving credit facility has a maturity date of July 1, 2021.

The first lien term loans and the revolving credit facility are both floating rate facilities, and RadNet may request that the interest rate thereon be based upon either an Adjusted Eurodollar Rate or a Base Rate (each as defined in the first lien credit agreement), plus an applicable margin.  After giving effect to the Amendment, the applicable margin for Eurodollar Rate loans under the first lien credit agreement will initially be 3.75% per annum and the applicable margin for Base Rate loans under the first lien credit agreement will be 2.75% per annum.  The applicable margin for Eurodollar Rate loans can adjust in the future to be as low as 3.25% per annum or as high as 4.5% per annum and the applicable margin for Base Rate loans can adjust in the future to be as low as 2.25% per annum or as high as 3.5% per annum, in each case based upon RadNet’s net debt leverage ratio.  Previously, the applicable margin on RadNet’s second lien term loans was 7.00% for Eurodollar Rate loans and 6.00% for Base Rate loans.

“We are very pleased to have been able to increase our senior secured first lien credit facilities and to retire our second lien credit facilities at this time,” said Mark Stolper, Executive Vice President and Chief Financial Officer of RadNet. “By completing this transaction, we were able to initially reduce our annual cash interest expense by almost $3 million. Based upon the pricing matrix in the Amendment, if we continue to deleverage our balance sheet in the future, we could save up to an additional $3 million of cash interest expense annually.  Furthermore, we were able to extend the maturities on the $168.0 million portion of term debt which was formerly our second lien loan by over two years.   Lastly, we significantly improved our financial flexibility.  Once again, we would like to thank our group of supportive lenders.”

The borrower under the first lien credit facilities is RadNet’s subsidiary, RadNet Management, Inc. The obligations of the borrower under the first lien credit facilities are guaranteed by RadNet, all of the borrower’s current and future wholly-owned domestic subsidiaries and certain of its affiliates. With certain exceptions, the obligations of the borrower and the guarantors under the first lien credit facilities are secured by substantially all of the assets of the borrower, RadNet and its subsidiaries and affiliates.

Barclays Bank PLC, Capital One, National Association, SunTrust Robinson Humphrey, Inc., Credit Suisse Securities (USA) LLC and RBC Capital Markets acted as joint bookrunners and joint lead arrangers in the transaction.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.  These forward-looking statements include, but are not limited to, statements related to the anticipated use of proceeds from the new credit facilities and statements regarding the Company’s future interest rate expense and financial flexibility.  Forward-looking statements are based on management’s current expectations as of the date of this press release and are subject to known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from the statements contained herein.  For additional information concerning risks, uncertainties and other factors that may cause actual results to differ from those anticipated in the forward-looking statements, and risks to the Company’s business in general, please refer to its SEC filings, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2016, as amended.  RadNet undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

About RadNet, Inc.
RadNet, Inc. is the leading national provider of free-standing, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue.  RadNet has a network of 298 owned and/or operated outpatient imaging centers.  RadNet’s core markets include California, Maryland, Delaware, New Jersey and New York.  In addition, RadNet provides radiology information technology solutions, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry.  Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has a total of approximately 7,300 employees. For more information, visit http://www.radnet.com.

Contact:

RadNet, Inc.
Mark Stolper
Executive Vice President and
Chief Financial Officer
310-445-2800

$ZN Travel to #Israel for Upcoming Well Operations

Zion prepares to log and case its MJ #1 well at 2,000 meters (6,560 feet)

DALLAS and CAESAREA, Israel, Aug. 22, 2017  —  Zion Oil & Gas, Inc. (NASDAQ: ZN)  makes preparations to obtain wireline logs and case the next well interval at a depth of approximately 2,000 meters (6,560 feet).

Victor Carrillo (CEO), Dustin Guinn (President), and Dr. Lee Russell (Senior Geoscience Advisor and Board Director) arrived in Israel this week to be on site for upcoming operations at Zion’s Megiddo-Jezreel #1 well.

Senior Geoscience Advisor, Dr. Russell explains, “Recent drilling over the last few hundred meters suggests the possible existence of a highly fractured carbonate section in the Jurassic, which presents optimism for potential reservoir characteristics. Carbonate reservoirs are prominent in the Middle East, with around 70% of oil and 90% of gas reserves held within these reservoirs. Based on the evidence of existing fractures, we are eager to see what the next logging run will show us.  There are multiple zones of interest through which we still plan to drill and evaluate as we drill towards our total depth.”

Zion President, Dustin Guinn, adds, “Given the formation characteristics that can be expected with highly fractured carbonates, we made the decision, to insure safety and well integrity, to case this interval at a shallower depth than previously anticipated. While this is a change to the drilling program, it is not expected to materially affect the expected total depth to which we hope to drill.   I am also excited about the formation characteristics and while it may present drilling challenges, it may also present reservoir characteristics that are intriguing.”

In 2015, an independent study by the international consulting company Beicip-Franlab concluded that up to 6.6 billion barrels of oil (in-place best estimate) remain to be found in Israel’s Levant Basin.  Zion’s Megiddo-Jezreel License area is entirely within the Levant Basin and is well positioned to encounter the key geologic ingredients of an active petroleum system.

Zion Oil & Gas explores for oil and gas onshore in Israel and its operations are focused on the Megiddo-Jezreel License (approximately 99,000 acres) south and west of the Sea of Galilee.

For more information on Zion Oil & Gas, go to www.zionoil.com/

Contact Info:
Zion Oil & Gas, Inc. (NASDAQ: ZN)
12655 North Central Expressway, Suite 1000
Dallas, TX 75243
Andrew Summey
Telephone: 888-891-9466
Email: andrew.summey@zionoil.com
www.zionoil.com

$CLRB Significant #PDC Platform Advancement, Enhanced Therapeutic Window

MADISON, Wis., Aug. 22, 2017  — Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today announces that its Phospholipid Drug Conjugate research program has generated numerous PDC molecules that show significant improved pharmacologic activity versus the payload molecule alone.

Utilizing a selection of novel linkers to attach proprietary cytotoxic molecules to the company’s PDC platform, Cellectar has formulated new compounds specifically designed for improved tumor targeting and fewer off-target adverse effects. The research has demonstrated that with a variety of payloads, the phospholipid ether molecules provide, on average, a greater than 20-fold increase in delivery of the PDC to cancerous cells.

To date, the company’s research has demonstrated that the conjugated molecules are inactive until cleavage of the payload from the phospholipid ether.  This mechanism provides significant opportunity to reduce the off-target impact and associated side effects of many chemotherapeutics.  These data show greater than 500-fold dilution separation between effects in tumor cells and effects in normal cells, and that this separation can be controlled by the linker chemistry. Importantly, the company has also been able to show that its novel linker chemistry allows for the payload to be selectively cleaved within the tumor cells, resulting in significant potency.

“The rapid advancement and positive data from these research programs, coupled with our ongoing collaborations, further validate the unique capabilities and broad utility of our PDC platform,” said Jim Caruso, president and CEO of Cellectar Biosciences.  “We continue to drive our key internal programs in a strategic and cost-efficient manner including the advancement of candidate molecules from these new compound series. The company anticipates sharing additional technical details of this work either in peer reviewed journal articles or at a future oncology conference.”

Cellectar is currently developing internal PDC programs, such as its CLR 131 clinical program and its preclinical programs, CLR 1700 and CLR 1900 series.  Additionally, the platform is the basis of two strategic collaborations with Pierre Fabre and Avicenna Oncology.

About Phospholipid Drug Conjugates (PDCs)
Cellectar’s product candidates are built upon its patented cancer cell-targeting delivery and retention platform of optimized phospholipid ether-drug conjugates (PDCs).  The company deliberately designed its phospholipid ether (PLE) carrier platform to be coupled with a variety of payloads to facilitate both therapeutic and diagnostic applications.  The basis for selective tumor targeting of our PDC compounds lies in the differences between the plasma membranes of cancer cells compared to those of normal cells.  Cancer cell membranes are highly enriched in lipid rafts, which are glycolipoprotein microdomains of the plasma membrane of cells that contain high concentrations of cholesterol and sphingolipids, and serve to organize cell surface and intracellular signaling molecules. PDCs have been tested in more than 80 different xenograft models of cancer.

About CLR 131
CLR 131 is an investigational compound under development for a range of hematologic malignancies.  It is currently being evaluated as a single-dose treatment in a Phase 1 clinical trial in patients with relapsed or refractory (R/R) multiple myeloma (MM) as well as in a Phase 2 clinical trial for R/R MM and select R/R lymphomas with either a one- or two-dose treatment. CLR 131 represents a novel approach to treating hematological diseases and based upon preclinical and interim Phase 1 study data may provide patients with therapeutic benefits including, overall survival, an improvement in progression-free survival, and overall quality of life. CLR 131 utilizes the company’s patented PDC tumor targeting delivery platform to deliver a cytotoxic radioisotope, iodine-131, directly to tumor cells. The FDA has granted Cellectar an orphan drug designation for CLR 131 in the treatment of multiple myeloma.

About Cellectar Biosciences, Inc.
Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells.  Cellectar’s PDC platform is based on the company’s proprietary phospholipid ether analogs.  These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers, even sites of metastases.  The company’s lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload.  CLR 131 has been designated as an orphan drug by the US FDA and is currently being evaluated in a Phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a Phase 2 clinical study to assess efficacy in a range of B-cell malignancies.   The company is also developing proprietary PDCs for targeted delivery of chemotherapeutics and has several preclinical stage product candidates, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts.  For more information please visit www.cellectar.com.

This news release contains forward-looking statements.  You can identify these statements by our use of words such as “may,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” “continue,” “plans,” or their negatives or cognates.  These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on our current beliefs and expectations as to such future outcomes.  Drug discovery and development involve a high degree of risk.  Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators’ ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.  A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2016.  These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

CONTACT: 
Jules Abraham
JQA Partners
917-885-7378
jabraham@jqapartners.com

$KIRK Solid Q2 Results

NASHVILLE, Tenn., Aug. 22, 2017 — Kirkland’s, Inc. (NASDAQ: KIRK) today reported financial results for the 13-week and 26-week periods ended July 29, 2017.

Net sales for the 13 weeks ended July 29, 2017 increased 7.0% to $131.7 million compared with $123.0 million for the 13 weeks ended July 30, 2016. Comparable store sales for the second quarter of fiscal 2017, including e-commerce sales, increased 1.2% compared with a decrease of 4.3% in the prior-year quarter. Kirkland’s opened eight stores and closed three during the second quarter, bringing the total number of stores to 406 at quarter end.

Net sales for the 26 weeks ended July 29, 2017, increased 4.6% to $264.5 million compared with $252.9 million for the 26 weeks ended July 30, 2016. Comparable store sales, including e-commerce, for the 26 weeks ended July 29, 2017 decreased 1.4% compared with a decrease of 1.8% in the prior-year period. Kirkland’s opened 16 stores and closed 14 during the 26-week period ended July 29, 2017.

For the 13 weeks ended July 29, 2017, the Company reported a net loss of $3.8 million, or ($0.24) per diluted share compared with a net loss of $3.6 million, or ($0.22) per diluted share, for the 13 weeks ended July 30, 2016. For the 26 weeks ended July 29, 2017, the Company reported a net loss of $5.2 million, or ($0.33) per diluted share compared with a net loss of $2.7 million, or ($0.17) per diluted share, for the 26 weeks ended July 30, 2016.

“Second quarter results were in line with our expectations and we continue to make demonstrable progress on our strategic initiatives to improve our merchandise assortment, optimize our promotional and marketing activity, and advance our overall operational execution,” said Mike Madden, Chief Executive Officer. “Sales were driven by better trends in existing stores, new store productivity, and continued momentum at kirklands.com. The merchandise margin was under pressure from our planned assortment adjustments and a promotional retail environment. We maintained disciplined expense control and ended the quarter in a better inventory position.”

“The balance sheet is in great shape, with a strong cash position and no debt outstanding on our revolving credit facility,” continued Mr. Madden. “The board has authorized a new share repurchase program, which reflects our long-held policy to use excess cash to enhance shareholder returns. We’ll also continue to invest in the business to further strengthen our execution, expand the omni-channel platform, and escalate our brand awareness.”

Fiscal 2017 Outlook

Kirkland’s maintained its fiscal 2017 outlook given on March 10, 2017, which provides for diluted earnings per share in the range of $0.50 to $0.65 for the full year.

This performance outlook is based on current information as of August 22, 2017. The information on which this outlook is based is subject to change, and the Company may update its full year business outlook or any portion thereof at any time for any reason.

Stock Repurchase Plan Authorization

The Board of Directors has authorized a stock repurchase plan providing for the purchase in the aggregate of up to $10 million of the Company’s outstanding common stock. Repurchases of shares will be made in accordance with applicable securities laws and may be made from time to time in the open market or by negotiated transactions. The amount and timing of repurchases will be based on a variety of factors, including stock acquisition price, regulatory limitations and other market and economic factors. The stock repurchase program does not require the Company to repurchase any specific number of shares, and the Company may terminate the repurchase program at any time. As of July 29, 2017, the Company had 16.0 million common shares outstanding.

Investor Conference Call and Web Simulcast

Kirkland’s will hold its earnings call for the second quarter later today at 11:00 a.m. ET. Participating on the call will be Mike Madden, President and Chief Executive Officer, and Nicole Strain, Interim Chief Financial Officer. The number to call for the interactive teleconference is (412) 542-4163. A replay of the conference call will be available through Tuesday, August 29, 2017, by dialing (412) 317-0088 and entering the confirmation number, 10111233.

A live webcast of Kirkland’s quarterly conference call will be available online on the Company’s Investor Relations Page on August 22, 2017, beginning at 11:00 a.m. ET. The online replay will follow shortly after the call and continue for one year.

About Kirkland’s, Inc.

Kirkland’s, Inc. was founded in 1966 and is a specialty retailer of home décor in the United States. Although originally focused in the Southeast, the Company has grown beyond that region and currently operates 408 stores in 36 states as well as an e-Commerce enabled website, www.kirklands.com.  The Company’s stores present a broad selection of distinctive merchandise, including framed art, mirrors, candles, lamps, picture frames, accent rugs, garden accessories and artificial floral products.  The Company’s stores also offer an extensive assortment of gifts, as well as seasonal merchandise.  More information can be found at www.kirklands.com.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Kirkland’s actual results to differ materially from forecasted results. Those risks and uncertainties include, among other things, the competitive environment in the home décor industry in general and in Kirkland’s specific market areas, inflation, possibility of new tax legislation, fluctuations in cost and availability of products, interruptions in supply chain and distribution systems, the ability to control employment, and other operating costs, availability of suitable retail locations and other growth opportunities, disruptions in information technology systems including the potential for security breaches of Kirkland’s or its customers’ information, seasonal fluctuations in consumer spending, and economic conditions in general. Those and other risks are more fully described in Kirkland’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K filed on March 31, 2017 and subsequent reports. Kirkland’s disclaims any obligation to update any such factors or to publicly announce results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments.

$NTEC Announces Closing of $57.5 Million Public Offering of Ordinary Shares

JERUSALEM, August 21, 2017 —

Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the closing of its previously announced offering of approximately 12.2 million of its ordinary shares, at a public offering price of $4.70 per ordinary share, which included a full exercise by the underwriters of their over-allotment option in the amount of 1,594,500 ordinary shares, for gross proceeds of approximately $57.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

Oppenheimer & Co. Inc. acted as the sole book-running manager, Roth Capital Partners acted as lead manager, and Maxim Group LLC acted as co-manager in the offering.

Intec Pharma intends to use the net proceeds from this offering to fund its Phase III clinical trial for Accordion Pill Carbidopa/Levodopa, the company’s leading product candidate for the indication of treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients, for working capital and for general corporate purposes.

The ordinary shares described above were issued pursuant to a shelf registration statement on Form F-3, previously filed with and subsequently declared effective by the Securities and Exchange Commission (SEC) on June 19, 2017. A final prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC and is available on the SEC’s website at http://www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to these ordinary shares may be obtained from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26^th Floor, New York, New York, 10004, or by telephone, at 212-667-8563, or e-mail at EquityProspectus@opco.com .

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Intec Pharma Ltd.

Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company’s Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company’s product pipeline includes two product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is being developed for the treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients, and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC), which is being developed for various indications including low back neuropathic pain and fibromyalgia.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. This press release contains forward-looking statements about the Company’s expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should,” “could,” “might,” “seek,” “target,” “will,” “project,” “forecast,” “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters, and include statements regarding the Company’s future or operating performance. These forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, and include the following: the company’s ability to develop and commercialize its product candidates and obtain additional financing necessary therefor; the length, cost and uncertain results of the company’s clinical trials; including uncertainty regarding the Company’s ability to enroll the required number of patients therein; the potential of adverse side effects, other safety risks, or legal prohibitions on the use of certain products in certain jurisdictions that could preclude the approval of the company’s drug candidates; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; and the influence of extensive and costly government regulation.

Contacts:
Jeffrey A. Meckler
Chief Executive Officer
Intec Pharma Ltd.
646-374-8050
jeffrey@intecpharma.com

Anne Marie Fields
Senior Vice President
LHA Investor Relations
212-838-3777
afields@lhai.com

$CSSE Ramps Up Video Content Production, Targets 2017 Revenue of $20M

Recent IPO Provides Capital Resources To Enhance 2018 Business Plan, Targeting Approximately $36 Million in Revenue and $18 Million in EBITDA

COS COB, Conn., Aug. 21, 2017 — Chicken Soup for the Soul Entertainment, Inc. (“CSS Entertainment”) (Nasdaq:CSSE), a fast-growing provider of positive and entertaining video content, today announced that the successful completion of its IPO provides the financing necessary to ramp up production of its television programming, including having already begun production on three series, as well as new online and other video content.

Based on the company’s post-IPO production schedule, CSS Entertainment is targeting 2017 revenue of $20 million and EBITDA of $10 million.

The IPO also provides CSS Entertainment with the capital resources to enhance its 2018 business plan, projected to result in approximate revenue of $36 million and EBITDA of $18 million.

“While working to complete our IPO, our operating team was preparing to ramp up production of television programming and other video content immediately upon closing,” stated William J. Rouhana, Jr., chairman and chief executive officer.  “We have already begun production on three series.”

These three series will air on major broadcast and/or cable networks.  The series will be included in their respective networks’ announcements for their upcoming programming lineups.  These series will also be distributed through CSS Entertainment’s online distribution channels, including through Aplus.com and its online network.

“Each of these three series is consistent with the company’s strategy of having a sponsor committed to funding a series prior to production,” said Scott W. Seaton, vice chairman and chief strategy officer.  “The company anticipates going into production on additional series in the coming months using this same approach.”

In addition to building its video content library through the production of original content, the company intends to pursue acquisitions of third-party video content libraries that are consistent with the Chicken Soup for the Soul brand, as well as other opportunistic acquisitions.

“Our IPO proceeds and public shares position us to make strategic acquisitions,” stated Mr. Rouhana.

The company is already engaged in ongoing discussions with strategic acquisition targets.  The outcome of such discussions with strategic acquisition targets may impact operating results.

ABOUT CHICKEN SOUP FOR THE SOUL ENTERTAINMENT

Chicken Soup for the Soul Entertainment, Inc. is a fast-growing provider of positive and entertaining video content that brings out the best of the human spirit. The Company is aggressively growing its business through a combination of organic growth, licensing and distribution arrangements, acquisitions, and strategic relationships. Chicken Soup for the Soul Entertainment is also expanding its partnerships with sponsors, television networks and independent producers. The Company will make its video content available to consumers globally through television and online networks, including its online affiliate APlus.com. The company is a subsidiary of Chicken Soup for the Soul, LLC.

FORWARD LOOKING STATEMENTS

This press release includes forward-looking statements that involve risks and uncertainties.  Forward looking statements are statements that are not historical facts.  Such forward-looking statements are subject to risks (including those set forth in the offering circular) and uncertainties which could cause actual results to differ from the forward looking statements.  The company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Investors should realize that if our underlying assumptions for the projections contained herein prove inaccurate or that known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections.

Use of Non-GAAP Financial Measures

This press release contains a non-GAAP financial measure (EBITDA), which is not recognized under GAAP, as a supplemental indicator of our operating performance. This non-GAAP financial measure is provided to enhance the readers understanding of our historical and current financial performance. EBITDA means earnings before interest, taxes, depreciation and amortization. Management believes EBITDA to be a meaningful indicator of our performance that provides useful information to investors regarding our financial condition and results of operations. The most comparable GAAP measure is operating income.

MEDIA CONTACT:
Jeanene Timberlake
RooneyPartners LLC
jtimberlake@rooneyco.com
(646) 770-8858

INVESTOR RELATIONS
Jody Burfening/Sanjay M. Hurry
LHA
CSSEnt@lhai.com
(212) 838-3777

$CHRS Private Placement from Temasek

First tranche of $75 million secured

REDWOOD CITY, Calif., Aug. 21, 2017  — Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced plans to raise up to $150 million in a two tranche private placement, the first tranche of $75 million in aggregate gross proceeds to be completed and funded by August 31, 2017 with 6,556,116 shares of common stock to be issued at an offering price of $11.44 per share.

Temasek, an investment company headquartered in Singapore, plans to invest up to $150 million over two tranches. The second tranche is projected to be funded following receipt of the U.S. Food and Drug Administration’s marketing approval for the CHS-1701 pegfilgrastim biosimilar product candidate, subject to market pricing and certain closing conditions at that time, including each party’s final approval.

Coherus intends to use the net proceeds from these private placements for additional capital for the completion of development and registration of the CHS-1701 pegfilgrastim biosimilar product candidate, the launch of CHS-1701, the development and registration of the CHS-1420 adalimumab biosimilar product candidate, the development of the CHS-3351 ranibizumab biosimilar product candidate, and for general corporate purposes.

“We are very pleased to have the support of a significant investor of Temasek’s stature and reputation as we continue to progress CHS-1701 and the rest of our pipeline,” commented Denny Lanfear, Coherus Chief Executive. “We are gratified to have Temasek as a shareholder as we advance our efforts to bring biosimilar competition to the market, delivering cost savings for the healthcare system and increasing access to essential biologics for patients.”

The securities to be sold in these private placements have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and will be sold in private placements pursuant to Regulation D of the Securities Act. The securities may not be offered or sold in the United States absent registration or pursuant to an exemption from the registration requirements of the Securities Act and applicable state securities laws. Coherus has agreed to file a registration statement covering the resale of the shares of common stock acquired by the investors.

About Coherus BioSciences, Inc.
Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com.

Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Coherus’ plans, potential opportunities, expectations, projections, goals, objectives, milestones, strategies, product pipeline, clinical studies, product development, release of data and the potential benefits of its products under development are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including the anticipated closings of each tranche of the private placement transactions, Coherus’ anticipated use of proceeds from the private placement transactions, and Coherus’ plans and strategy to advance clinical products towards commercialization, including the potential receipt of marketing approval for the CHS-1701 pegfilgrastim biosimilar product candidate. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of our regulatory filings and other matters that could affect the availability or commercial potential of our biosimilar drug candidates, as well as possible patent litigation. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ Annual Report on Form 10-K for the period ended December 31, 2016, filed with the Securities and Exchange Commission on March 14, 2017, its Quarterly Report on Form 10-Q for the period ended June 30, 2017, filed with the Securities and Exchange Commission on August 7, 2017 and its future periodic reports to be filed with the Securities and Exchange Commission.

Contact:
Patrick O’Brien
Senior Vice President, Investor Relations
Coherus BioSciences, Inc.
pobrien@coherus.com
+1 (650) 649-3527

$ARCI Second Quarter 2017 Financial Results

MINNEAPOLIS, Aug. 21, 2017 — Appliance Recycling Centers of America, Inc. (Nasdaq: ARCI) (“ARCA” or the “company”), a leading provider of utility appliance recycling programs, announces today its financial results for the second quarter of 2017.

Highlights, which are comparable to the same period of 2016, include:

• Revenues of $25.7 million, an increase of 4.1 percent
• Gross profit of $8.7 Million, an increase of 35 percent
• Operating Income of $2.5 Million, compared to a loss of $1.1 Million
• SG&A of $6.1 Million, a reduction of 18 percent
• Net Income of more than $2 Million, or, $0.31 earnings per share, compared to a previous loss of $2.1 Million
• Cash flow from operations of approximately $3.3 Million for the 26 weeks ended July 1, 2017
• Stockholders Equity increased to $15.1 Million ($2.27 per share), an increase of 40.1 percent year to date

“We have diligently worked over the last several quarters to improve our company balance sheet and streamline operations in order to achieve our current position, of which we are extremely pleased,” said Tony Isaac, CEO of ARCA.  “Our work has been focused on reducing expenses, repositioning of our company, and selling our stake in our joint venture, ARCA Advanced Processing, the results of which are not included in these financial statements, but have improved our balance sheet through the receipt of $800,000 in cash and the elimination of more than $4.2million in direct and indirect liabilities, as well as preventing associated potential future losses. Ultimately we believe these efforts result in additional shareholder value.”

About ARCA

ARCA’s two business components are uniquely positioned in the industry to work together to provide a full array of appliance-related services. ARCA’s regional centers process appliances at end of life to remove environmentally damaging substances and produce material byproducts for recycling for utilities in the U.S. and Canada. Eighteen company-owned stores under the name ApplianceSmart, Inc.® sell new appliances directly to consumers and provide affordable ENERGY STAR® options for energy efficiency appliance replacement programs.

Forward Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including statements regarding ARCA’s future success. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the statements made, including the risks associated with the general economic conditions, competition in the retain and recycling industries and regulatory risks. Other factors that could cause operating and financial results to differ are described in ARCA’s periodic reports filed with the Securities and Exchange Commission. Other risks may be detailed from time to time in reports to be filed with the SEC.

$IGC Announces Financial Results for Quarter Ended June 30, 2017

Alzheimer’s Licensing Agreement Highlights Cannabis-Based IP Portfolio Targeting Large Market Conditions

BETHESDA, Md., Aug. 21, 2017 — India Globalization Capital, Inc. (NYSE AMERICAN:IGC) announces financial results for the quarter ended June 30, 2017.

“During the quarter, we secured an IP licensing agreement from the University of South Florida addressing a potential treatment for Alzheimer’s disease.  This patent filing claims discovery of a new pathway: low doses of THC bind to amyloid beta plaques and prevent those plaques from aggregating on neurons, which is what occurs in Alzheimer’s disease and causes cognitive decline.  IGC expects to release mouse data showing that this pathway and therapy have possible blockbuster potential in treating Alzheimer’s disease.  We expect to take this exciting treatment to human medical trials as soon as possible,” stated Ram Mukunda, CEO of IGC.

Total revenue was $52,926 for the three months ended June 30, 2017, as compared to $288,493 for the three months ended June 30, 2016. The decrease in revenue is attributable to the corporate mandate to extricate IGC from the electronic and iron ore trading businesses and focus management on medical cannabis therapies. The revenue in the three months ended June 30, 2017 is all from the rental of heavy equipment and real estate management.

Selling, general and administrative expenses were $436,351 for the quarter ended June 30, 2017 as compared to $307,772 for the quarter ended June 30, 2016.  Most of these expenses are a result of public-company expenses, including legal fees.

The Company reported a consolidated GAAP net income loss of $432,141 and a GAAP EPS loss of $0.02 compared to a GAAP net income loss of $383,566 and a GAAP EPS loss of $0.02 for the three months ended June 30, 2016. The increase in loss is due to increased SG&A related to marketing programs that the company initiated.

For the quarter ended June 30, 2017, our non-GAAP cash burn was approximately $389,577.

At the end of June 30, 2017, our cash and cash equivalents along with restricted cash was $345,610 with working capital of $623,984. We anticipate securing additional capital to further our patent portfolio and commence medical trials on our Alzheimer’s product.

About IGC

IGC develops cannabis-based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in humans, dogs and cats.  In support of this effort, IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. We are based in Bethesda, Maryland.

Our website: www.igcinc.us.  Twitter @IGCIR Facebook.com/IGCIR/

Forward-looking Statements

Please see forward-looking statements as discussed in detail in IGC’s Form 10-K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.

FINANCIAL STATEMENTS TO FOLLOW

Contact

Claudia Grimaldi
301-983-0998

$CIIX to Attend the Southern California Investment Forum and MoneyShow San Francisco

SAN GABRIEL, California, August 21, 2017 —

ChineseInvestors.com, Inc. (OTCQB: CIIX) (“CIIX” or the “Company”), the premier financial information website for Chinese-speaking investors, announces that it will attend the Southern California Investment Forum (“SCIF”), taking place August 24, 2017, at Morton’s Steakhouse in San Francisco. The Company will also attend the MoneyShow conference at the Marriott Marquis in San Francisco, taking place August 24 – 26, 2017.

The SCIF introduces emerging small cap public and private companies from around the world to interested investors. The Forum provides investors with a unique opportunity to have direct contact with Company executives. CIIX will provide attendees with business updates regarding its financial services/media division and its direct to consumer division, which focuses on the marketing and sale of non-industrial hemp health products.

The MoneyShow is a global network that provides investment and trading education and hosts live and online events attracting over 75,000 potential investors, traders, and financial advisors from around the world. The conference has devoted one day to cover new investment opportunities in cannabis – one of the fastest growing market sectors – which is significant to CIIX’s new direct-to-consumer division focused on non-industrial hemp health products.

In addition, the Company is excited to announce its partnership with Weibo whereby it will broadcast its daily stock commentary program, “US Stock Billionaire,” as well as roadshow and conference reports on Weibo’s official YouTube channel. Currently, the official Weibo YouTube channel has more than 300,000 subscribers. The Company is confident that its partnership with Weibo will draw even more attention to the Company’s programs, events and business updates.

“I am delighted that CIIX has been invited to attend the Southern California Investment Forum and MoneyShow San Francisco,” says Warren Wang, Founder and CEO of CIIX. “MoneyShow hosts one of the most well-known investor conferences, which attracts traders and financial advisors from all over the world providing the Company with a valuable opportunity to network with top market experts, analysts and media companies. We encourage attendees to visit our booth at MoneyShow to learn more about CIIX and the incredible opportunities that await.”

About ChineseInvestors.com (OTCQB: CIIX)

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail, online sales and direct sales of hemp-based products and other health related products.

For more information visit ChineseInvestors.com

Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom

Follow us on Twitter for real-time Company updates: https://twitter.com/ChineseFNEnglsh

Like us on Facebook to receive live feeds: https://www.facebook.com/Chinesefncom

https://www.facebook.com/Chineseinvestors.com.english

Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Contact:
ChineseInvestors.com, Inc.
227 W. Valley Blvd, #208 A
San Gabriel, CA 91776
Investor Relations:
Alan Klitenic
+1-214-636-2548
Corporate Communications:
NetworkNewsWire (NNW)
New York, New York
http://www.NetworkNewsWire.com
212-418-1217 Office
Editor@NetworkNewsWire.com

$MDXG Definitive Agreement to Divest Stability Biologics Subsidiary

MARIETTA, Ga., Aug. 18, 2017 — MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that it has signed a definitive agreement with the former stockholders of Stability Inc. to divest the Company’s subsidiary, Stability Biologics LLC (f/k/a Stability Inc.) back to those stockholders.

The recent announcement by the Company to transition into a biopharmaceutical company was an impetus for this divestiture initiative.  Acquired by MiMedx in January 2016, Stability Biologics developed and processed bioactive bone graft products and tissue allografts including structural/particulate bone, structural allografts, demineralized bone matrix (DBM), skin products for burns and traumatic wound care, and Physio®, a bone grafting material. MiMedx acquired Stability Biologics with a combination of cash and stock paid at closing, with future contingent consideration to be paid through a two-year earn-out arrangement.

Parker H. “Pete” Petit, MiMedx CEO, said, “We remain very confident in our growth trajectory continuing and in our ability to meet or exceed the revenue projections we have previously set for 2017. In our press release of July 26, 2017, we raised our annual revenue guidance to the range of $309 million to $311 million. Assuming this transaction closes in the third quarter, we will maintain our full year revenue guidance. Even without the Stability Biologics revenue contribution in the fourth quarter, we are confident in our ability to meet our increased revenue guidance for the year. As such, we are also reaffirming all other guidance ranges for the third quarter and full year 2017 as communicated in our July 26 press release.”

Petit added, “We have determined that the Stability Biologics business is not a strategic fit with our new focus on becoming predominantly a biopharmaceutical company. While we believe the potential of Stability Biologics products continues to be significant, we expect to have better return on investment (ROI) opportunities in biopharma compared to those in the cadaver tissue category. A major incentive for the MiMedx acquisition of Stability Biologics was its independent sales representative organization. As part of the transaction, MiMedx will retain access to this sales rep organization via a distributor agreement with Stability. This group of sales reps will continue to focus on certain areas of our surgical business.”

Petit continued, “Our human placental tissue allografts are the source material for our primary asset base, which is a key technology differentiator in regenerative biologics. We are focusing our efforts on continuing down the Investigational New Drug/Biologics License Application (IND/BLA) regulatory pathways for numerous new therapeutic applications of our placental-based technology.  MiMedx will continue to demonstrate, through scientific and clinical studies and trials, the clinical and economic effectiveness of our regenerative biologics and therapies. After this divesture, MiMedx’s gross profit and operating profit margins are expected to improve.”

Mike Senken, MiMedx CFO, commented, “The transaction is expected to be completed in the third quarter of 2017, and the consideration will include a promissory note issued by Stability Biologics in the principal amount of $3.5 million in favor of MiMedx and a waiver by the former stockholders of Stability, Inc. of all claims and rights to the Earn-Out consideration. The Company expects to book a one-time gain on this transaction of approximately $8 million to $10 million.”

Bill Taylor, MiMedx President and COO, commented, “Our infrastructure has been carefully adjusted and assembled to pursue our biopharma strategy. With this new strategic focus, the long-term strategy of Stability Biologics is no longer a strategic fit for MiMedx. That said, through a new “private label” distribution agreement with Stability Biologics, we have retained their key sales relationships for the spine and orthopedics areas of our surgical business.”

Brian Martin, CEO of Stability Biologics LLC, added, “We have enjoyed our association with MiMedx and believe we have benefited a great deal during our time as part of the MiMedx organization. We believe this transaction is a very positive event for both companies.”

About MiMedx

MiMedx® is a biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare. “Innovations in Regenerative Medicine” is the framework behind our mission to give physicians products and tissues to help the body heal itself. We process the human placental tissue utilizing our proprietary PURION® Process among other processes, to produce safe and effective allografts. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. MiMedx is the leading supplier of placental tissue, having supplied over 1,000,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare. For additional information, please visit www.mimedx.com.

Important Cautionary Statement 

This press release includes forward-looking statements, including statements regarding the Company’s confidence in its overall growth trajectory in 2017 and ability to meet revenue projections for the year even without revenue from Stability Biologics, the Company’s expectations regarding the gain on the transaction, the Company’s belief that the potential for Stability Biologics continues to be significant, the Company’s belief that it will have better return on investment in the biopharma category compared to cadaver tissue, that the Company’s placental tissue allografts are its technology differentiator, that the Company will continue to be able to demonstrate the clinical and economic effectiveness of its regenerative biologics and therapies, the Company’s belief that its gross profit and operating margins will improve post-divestiture, and the Company’s belief that the distributor agreement with Stability Biologics retains key sales relationships for the Company. Forward-looking statements also may be identified by words such as “believe,” “except,” “may,” “plan,” “potential,” “will” and similar expressions, and are based on our current beliefs and expectations.

Forward-looking statements are subject to significant risks and uncertainties, and we caution investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that any of the Company’s growth, revenue, and gross profit and operating margins may not continue as expected or may decline, Stability Biologics may not continue to have great potential post-divestiture, that the financial impact of the transaction may not occur as predicted, that the Company may not experience better return on investment in biopharma over cadaver tissue or may not be able to adequately transition into the biopharma space to realize its perceived advantages, that the Company’s placental tissue allografts do not continue to be a technology differentiator as competition increases and/or new and different technologies are developed, and that the distributor agreement may fail to retain key sales relationships for the Company. For additional risks that might affect the Company, please review the Risk Factors section of our most recent annual report or quarterly report filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and we assume no obligation to update any forward-looking statement.

$CSBR PDX Research Collaboration with The Addario Lung Cancer Medical Institute

HACKENSACK, N.J., Aug. 18, 2017  — Champions Oncology, Inc. (NASDAQ: CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced a collaboration with The Addario Lung Cancer Medical Institute “ALCMI” to develop a novel cohort of PDX models in patients with ROS1 gene rearrangement.  These models will further expand Champions’ TumorGraft bank offerings in non-small cell lung cancer for translational oncology research for academic and industry customers.  Champions’ global infrastructure will be leveraged to support this multi-year program.

As a patient-driven initiative, ALCMI is leading an international study, with Champions Oncology contributing its extensive experience and global infrastructure, to support the establishment of patient derived xenograft models from patients with a ROS1 fusion. The unique cohort of PDX models can be used as a resource for clinical and translational research and support development of new therapies in patients with ROS1 positive cancer.  The models established will have complete clinical and molecular annotation.

“Champions Oncology is pleased to partner with ALCMI for this patient-driven initiative to establish a unique cohort of models in ROS1 positive cancers,” said Angela M. Davies, MD, Chief Medical Officer, Champions Oncology Inc.

“Champions and ALCMI are combining their respective infrastructure, expertise and scientific commitment to build PDX models in this rare subtype of cancer and make those models available to academic and industry researchers,” Dr. Davies said. “This PDX resource will facilitate development of new therapies and understanding mechanisms of resistance in ROS1 cancers.”

“We are pleased to partner with Champions Oncology, and the ROS1 patient community, to help advance our shared goal of new and more effective therapies for affected lung cancer patients everywhere, via the creation and distribution of these much-needed research and development models,” said Steven Young, ALCMI President & COO.

About ALCMI

The Addario Lung Cancer Medical Institute (ALCMI, voiced as “Alchemy”), founded in 2008 as a 501(c)(3) non-profit organization by lung cancer survivor Bonnie J. Addario, is a patient-centric, international research consortium driving research otherwise not possible. Working in tandem with its “partner” foundation the Bonnie J. Addario Lung Cancer Foundation (ALCF), ALCMI powers collaborative initiatives in genetic (molecular) testing, therapeutic discoveries, targeted treatments and early detection. ALCMI overcomes barriers to collaboration via a world-class team of investigators from 26 member institutions in the USA, UK, and Europe, supported by dedicated, centralized research infrastructures such as standardized biorepositories and data systems. ALCMI directly facilitates research by combining scientific expertise found at leading academic institutions with patient access through its network of community cancer centers – accelerating novel research advancements to lung cancer patients. By providing access to critical masses of patient stakeholders, academic, community and industry researchers, ALCMI and ALCF are making progress towards their shared goal of transforming lung cancer into a chronically managed disease by 2023.

About Champions Oncology

Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The company’s technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune-deficient mice to create TumorGrafts that preserve the biological characteristics of the original human tumor to determine the efficacy of a treatment regimen. The company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. For more information, please visit www.championsoncology.com.

$CTRL Set to Join S&P SmallCap 600

NEW YORK, Aug. 17, 2017  — Control4 Corp. (NASD: CTRL) will replace Albany Molecular Research Inc. (NASD: AMRI) in the S&P SmallCap 600 effective prior to the open on Tuesday, August 22. The Carlyle Group and GTCR LLC are acquiring Albany Molecular Research in a deal expected to be completed soon, pending final conditions.

Control4 provides smart home and business solutions for the connected home or business. Headquartered in Salt Lake City, UT, the company will be added to the S&P SmallCap 600 GICS (Global Industry Classification Standard) Electronic Equipment & Instruments Sub-Industry index.

Following is a summary of the change:

For more information about S&P Dow Jones Indices, please visit www.spdji.com

ABOUT S&P DOW JONES INDICES

S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500^® and the Dow Jones Industrial Average^®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has become home to over 1,000,000 indices across the spectrum of asset classes that have helped define the way investors measure and trade the markets.

S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

FOR MORE INFORMATION:

S&P Dow Jones Indices
index_services@spglobal.com

David Blitzer
Managing Director and Chairman of the Index Committee
New York, USA
(+1) 212 438 39077
david.blitzer@spglobal.com

Soogyung Jordan
Global Head of Communications
New York, USA
(+1) 212 438 2297
soogyung.jordan@spglobal.com

Luke Shane
North America Communications
New York, USA
(+1) 212 438 8184
luke.shane@spglobal.com

Haw-Yan Man
EMEA Communications
London, UK
(+44) 207 176 3023
haw-yan.man@spglobal.com

Cecilia Ho
Asia Pacific Communications
Hong Kong, HK
(+852) 2532 8061
cecilia.ho@spglobal.com

$SENS Announces Pricing of Public Offering of Common Stock

GERMANTOWN, Md.

$IPDN to Partner at Women’s Forum 2017 Global Meeting

The Company’s President, Star Jones, a 9-time Emmy-nominated television personality, legal correspondent and global thought leader on women’s issues, to be a featured speaker in Paris, France October 5-6, 2017

CHICAGO, Aug. 18, 2017 — Professional Diversity Network, Inc. (NASDAQ:IPDN) (“PDN” or the “Company”), a global developer and operator of online and in-person networks that provides access to networking, training, educational and employment opportunities for diverse professionals, today announced that it is a partner with the Women’s Forum for the Economy & Society (“Women’s Forum”) and that its President, Star Jones, will be a featured speaker at the Women’s Forum 2017 Global Meeting (“WFGM event”).

Event Highlights

• The Women’s Forum is the world’s leading platform featuring women’s voices on major social and economic issues
• Flagship WFGM event to be held October 5-6, 2017 in Paris, with an anticipated 70 countries represented by over 1,500 delegates

The Company’s President, Star Jones, will be a featured speaker, presenting workshops and participating in plenary sessions on “Creating impact through women’s networks” and “How businesses can be more ‘human’.”

The WFGM event is the premiere event of its kind, designed to build bridges between generations – between young entrepreneurs, for example, and role models – having as its theme Engage for Impact! Daring to Lead in a Disrupted World.

The Company has agreed to partner with the Women’s Forum and is a sponsor at the WFGM event.  Management believes that this relationship, on this global stage, is highly beneficial to its membership in the NAPW (U.S.) and IAW (China) women’s paid professional networking segments because it enhances the Company’s brand recognition while contributing to the global discussion of critical issues from women’s perspective, which combine to add to the lifetime value of the Company’s paid networking memberships.

Ms. Jones noted that “PDN’s participation at the Women’s Forum Global Meeting is another example of our place in the global conversation on women’s issues and commitment to our members. We have previously disclosed our long-term plan to enhance the lifetime value of our networking memberships, including those we are now beginning to sell through our IAW segment in China.  I believe that this event dovetails perfectly with that plan because it brings global attention to women’s issues, which grows awareness of networking, while specifically spotlighting our brand within that broader conversation.  At the same time, it reinforces what we do for women every day, including supporting our nearly 150 local chapters in the U.S., our eChapters, eCoaching, and the like.  I am very proud, once again, to showcase our company on this prestigious, global stage.”

More information about the Women’s Forum and its WFGM event can be found on its website at: http://www.womens-forum.com/meetings/global-meeting-2017.

About Professional Diversity Network (PDN)

Professional Diversity Network, Inc. (PDN) is a global developer and operator of online and in-person networks that provides access to networking, training, educational and employment opportunities for diverse professionals. We operate subsidiaries in the United States and China including Noble Voice, a career placement and career counseling call center and National Association of Professional Women (NAPW), which is one of the largest, most recognized networking organizations of professional women in the country, spanning more than 200 industries and professions. Through an online platform and our relationship recruitment affinity groups, we provide our employer clients a means to identify and acquire diverse talent and assist them with their efforts to comply with the Equal Employment Opportunity Office of Federal Contract Compliance Program. Our mission is to utilize the collective strength of our affiliate companies, members, partners and unique proprietary platform to be the standard in business diversity recruiting, networking and professional development for women, minorities, veterans, LGBT+ and disabled persons globally.

Forward-Looking Statements

This press release contains certain forward-looking statements based on our current expectations, forecasts and assumptions that involve risks and uncertainties. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity. Forward-looking statements in this release are based on information available to us as of the date hereof. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business, which include the risk factors disclosed in our most recently filed Annual Report on Form 10-K and in our subsequent filings with the Securities and Exchange Commission. Forward-looking statements include statements regarding our expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “should,” and “would” or similar words. We assume no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise. Our most recently filed Annual Report on Form 10-K, together with this press release and the financial information contained herein, are available on our website, www.ipdnusa.com. Please click on “Investor Relations.”

CONTACT: Professional Diversity Network, Inc.

Jason Assad – Investor Relations
jwassad@prodivnet.com
678-570-6791

Chris Wesser – EVP and Secretary
cwesser@prodivnet.com
516-659-8560

Jim Kirsch – Co Executive Chairman
jkirsch@prodivnet.com
312-614-9021

$CUI To Participate, Midwest IDEAS Investor Conference, Aug 30, Chicago

TUALATIN, Ore., Aug. 17, 2017  — CUI Global, Inc. (NASDAQ: CUI) today announced its participation at the Midwest IDEAS Investor Conference on Wednesday, August 30, 2017 in Chicago, IL.

William Clough, chairman, president, and chief executive officer, is scheduled to present on that day at 11:20 am CT/12:20 pm ET. Mr. Clough will be joined by Daniel Ford, chief financial officer and chief operating officer of Energy Division, to host one-on-one meetings with institutional investors throughout the day.

Management’s presentation will be webcast live and available for replay on the Investor Relations section of the CUI Global, Inc. website, www.cuiglobal.com.

To attend or learn more about CUI Global’s participation at the Conference, please contact Sanjay M. Hurry at 212-838-3777 or shurry@lhai.com.

About CUI Global, Inc. 

Delivering Innovative Technologies for an Interconnected World . . .

CUI Global, Inc. is a publicly traded company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. From Orbital Gas Systems’ advanced GasPT platform targeting the energy sector, to CUI Inc.’s digital power platform serving the networking and telecom space, CUI Global and its subsidiaries have built a diversified portfolio of industry leading technologies that touch many markets. As a publicly traded company, shareholders are able to participate in the opportunities, revenues, and profits generated by the products, technologies, and market channels of CUI Global and its subsidiaries. But most importantly, a commitment to conduct business with a high level of integrity, respect, and philanthropic dedication allows the organization to make a difference in the lives of their customers, employees, investors and global community.

For more information please visit www.cuiglobal.com.

Important Cautions Regarding Forward Looking Statements

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The Company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, our reliance on third-party manufacturers and suppliers, government agency budgetary and political constraints, new or increased competition, changes in market demand, and the performance or reliability of our products. These factors and others could cause operating results to vary significantly from those in prior periods, and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the Company and its operations, are included in certain forms the Company has filed with the Securities and Exchange Commission.

$MDVX Names Charlie Farrahar CFO

$YERR Announces Listing on The Nasdaq Global Select Market

$DRIO Raises $4.28 Million Through Private Placement Offerings

CAESAREA, Israel, August 17, 2017 — DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health Company with mobile health and big data solutions, announced today that it has signed securities purchase agreements with domestic and non-U.S. investors for the sale of shares of the Company’s common stock and shares of the Company’s newly designated Series B Convertible Preferred Stock in concurrent private placement offerings. The Company expects to conduct a closing with respect to the offerings on or before August 22, 2017. Current shareholders have executed securities purchase agreements accounting for 54% of the securities to be sold in the offerings.

As a part of these private placement transactions, which totals $4.28 million in the aggregate before expenses and placement agent fees, the Company will issue 483,333 shares of common stock at a price per share of $1.80 and 1,894,446 shares of Series B Convertible Preferred Stock at a price per share of $1.80. The Series B Preferred Stock is convertible into shares of the Company’s common stock at a 1:1 ratio and provides for a 6% dividend payable upon the conversion of the preferred shares. The holders of the Series B Preferred Stock will not be entitled to convert such preferred stock into shares of the Company’s common stock until the Company obtains stockholder approval for such issuance. The Company has agreed to file a registration statement covering the resale of the shares of common stock sold in the offering, the shares of common stock underlying the Series B Convertible Preferred Stock and the shares of common stock issuable upon the payment of the dividend, within 60 days of closing.

The private placement was managed by the Company with the assistance of Aegis Capital Corp., which acted as the placement agent for a portion of the offerings.

The securities described herein have not been registered under the Securities Act of 1933, as amended, and may not be sold in the United States absent registration or an applicable exemption from the registration requirements.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About DarioHealth Corp.

DarioHealth Corp. is a leading global digital health company serving tens of thousands of users with dynamic mobile health solutions. We believe people deserve the best tools to manage their treatment, and harnessing big data, we have developed a unique way for our users to analyze and personalize their diabetes management. With our smart diabetes solution, users have direct access to track and monitor all facets of diabetes, without having the disease slow them down. The acclaimed Dario™ Blood Glucose Monitoring System all-in-one blood glucose meter and native smartphone app gives users an unrivaled method for self-diabetes management. DarioHealth is headquartered in Caesarea, Israel with a regional office in Burlington, Massachusetts. For more information, visit http://mydario.investorroom.com/.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. (the “Company”) related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue” are intended to identify forward-looking statements. For example, forward-looking statements are used in this press release when the Company discusses the proposed timing of the closing of the offerings. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate and Media Contact:
Shmuel Herschberg
Marketing Director
shmuel@mydario.com
+1-914-775-5548

DarioHealth Investor Relations Contact:
Hayden IR
Stephen Hart
DRIO@HaydenIR.com
+1-917-658-7878

$NETE PayOnline Payment Acceptance for Telegram, Viber, Facebook, & VK Apps

Instant payments module to reach a rapidly growing market of instant messaging (IM) users

$NTEC Announces Pricing of $50.0 Million Public Offering of Ordinary Shares

JERUSALEM, August 16, 2017 —

Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the pricing of an underwritten public offering of approximately 10.6 million of its ordinary shares at a public offering price of $4.70 per ordinary share. The gross proceeds of the offering are expected to be approximately $50.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

The offering is expected to close on or about August 21, 2017, subject to customary closing conditions. Intec Pharma has granted the underwriters a 30-day option to purchase up to approximately 1.6 million additional ordinary shares to cover over-allotments.

Oppenheimer & Co. Inc. is acting as the sole book-running manager, Roth Capital Partners is acting as lead manager, and Maxim Group is acting as co-manager in the offering.

If the over-allotment option is exercised in full, gross proceeds of the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $57.5 million.

Intec Pharma intends to use the net proceeds from this offering to fund its Phase III clinical trial for Accordion Pill Carbidopa/Levodopa, the company’s leading product candidate for the indication of treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients, for working capital and for general corporate purposes.

The ordinary shares described above will be issued pursuant to a registration statement on Form F-3 previously filed with and subsequently declared effective by the Securities and Exchange Commission (SEC) on June 19, 2017. A preliminary prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC and is available on the SEC’s website at http://www.sec.gov.

Before buying any ordinary shares of Intec Pharma in the offering, you should carefully read the preliminary prospectus supplement and the accompanying prospectus, together with the information incorporated by reference therein. These documents contain important information that you should consider when making your investment decision. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to these ordinary shares may be obtained from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26^th Floor, New York, New York, 10004, or by telephone, at 212-667-8563, or e-mail at EquityProspectus@opco.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Intec Pharma Ltd.

Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company’s Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company’s product pipeline includes two product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is being developed for the treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients, and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC), which is being developed for various indications including low back neuropathic pain and fibromyalgia.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. This press release contains forward-looking statements about the Company’s expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should,” “could,” “might,” “seek,” “target,” “will,” “project,” “forecast,” “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters, and include statements regarding the proposed public offering and the intended use of proceeds from the offering. These forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, and include the following: the company’s ability to develop and commercialize its product candidates and obtain additional financing necessary therefor; the length, cost and uncertain results of the company’s clinical trials; including uncertainty regarding the Company’s ability to enroll the required number of patients therein; whether the Company will be able to complete the offering of ordinary shares, market conditions, and the Company’s ability to fulfill required closing conditions; the potential of adverse side effects, other safety risks, or legal prohibitions on the use of certain products in certain jurisdictions that could preclude the approval of the company’s drug candidates; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; and the influence of extensive and costly government regulation.

Contacts:
Jeffrey A. Meckler
Chief Executive Officer
Intec Pharma Ltd.
+1-646-374-8050
jeffrey@intecpharma.com

Anne Marie Fields
Senior Vice President
LHA Investor Relations
+1-212-838-3777
afields@lhai.com

$XPLR Appoints Robert McFarland to Its Board of Directors

AUSTIN, Texas, Aug. 16, 2017 — Xplore Technologies Corp. (NASDAQ:XPLR) today announced that it has appointed Robert N. McFarland as a director of the Company. McFarland will fill the vacancy left by the previously announced resignation of Brian E. Usher-Jones, who agreed to continue to serve on the Board of Directors until his replacement was identified and duly appointed or elected to the Board of Directors. McFarland qualifies as an independent director, as defined under The NASDAQ Stock Market Rules.

Phil Sassower, Chairman of Xplore, said: “Bob brings extensive executive management experience with domestic and international enterprises, as well as years of experience with federal government IT services. We look forward to his insights as an independent director as we work to grow revenue in both current and prospective market opportunities. We also wish to thank Brian Usher-Jones for many years of dedicated service as a member of Xplore’s board. Brian has been a key part of our development over the years, and we wish him well.”

Most recently, McFarland served as Assistant Secretary for Information and Technology in the Department of Veterans Affairs (VA) from January 2004 through his retirement in 2006. In this role, he served as Chief Information Officer, advising the Secretary of Veterans Affairs on all matters pertaining to acquisition and management of IT systems. He was also responsible for overseeing operation of the VA’s computer systems and telecommunication networks for medical information, veterans’ benefits payments, life insurance programs and financial management systems.

Prior to his tenure at the VA, McFarland served as vice president of governmental relations for Dell Computer Corporation. He joined Dell in 1996 as vice president and general manager of the federal business segment. He held several senior executive positions at Dell, including managing the company’s global segment, large corporate accounts and government sector. Under his leadership, Dell became the number one supplier of computer systems to the federal government. In 1998 McFarland was named to the “Federal 100” – a joint government and industry award designating the top 100 executives in the federal marketplace.

McFarland’s information technology career also includes executive experience with additional domestic and international enterprises, including senior vice president for the Cerplex Group, Inc., of Southern California, a provider of outsourcing for electronics repair and distribution, and vice president of the Asia Pacific and Middle East regions of AST Research, Inc.

About Xplore Technologies
Xplore is The Rugged Tablet Authority™, exclusively manufacturing powerful, long-lasting, and customer-defined rugged tablet PCs since 1996. Today, Xplore offers the broadest portfolio of genuinely rugged tablets – and the most complete lineup of rugged tablet accessories – on Earth. Its mobility solutions are purpose-built for the energy, utilities, telecommunications, military and defense, manufacturing, distribution, public safety, healthcare, government, and field service sectors.   The company’s award-winning military-grade computers are also among the most powerful and longest lasting in their class, built to withstand nearly any hazardous condition or environmental extreme for years without fail.  Visit www.xploretech.com for more information on how Xplore and its global channel partners engineer complete mobility solutions to meet specialized workflow demands. Follow us on Twitter, Facebook, LinkedIn, and YouTube.

Forward Looking Statements
This news release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. When used in this document, the words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions are intended to identify forward-looking statements. Such statements reflect Xplore’s current views with respect to future events and are subject to such risks and uncertainties. Many factors could cause actual results to differ materially from the statements made including those factors detailed from time to time in filings made by Xplore with securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated or expected. Xplore does not intend and does not assume any obligation to update these forward-looking statements.

Contact Information:
Tom Wilkinson, Chief Financial Officer
Phone: (512) 637-1162
Email: twilkinson@xploretech.com

Matt Kreps, Darrow Associates Investor Relations
Phone: (512) 696-6401
Email: xplr@darrowir.com

$IDXG Announces Coverage of Thyroid Test by Oxford Health Plans

One of the Northeast’s Largest Health Plans Adds Coverage for ThyraMIR®

PARSIPPANY, N.J., Aug. 16, 2017 — Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or “the Company”), a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, announced today that Oxford Health Plans will cover Interpace’s ThyraMIR® test for indeterminate thyroid nodules effective August 1, 2017.   Oxford Health Plans, a UnitedHealthcare company, offers health care benefits to employers and individuals primarily in New York, New Jersey, and Connecticut making it one of the largest health plans in the heavily populated tri-state Region.  Oxford’s commercial insured products and services include traditional health maintenance organizations, preferred and exclusive provider organizations, point-of-service plans and consumer-driven health plans.  In addition, Oxford also offers Medicare plans and third-party administration of employer-funded benefits plans.

With the addition of Oxford’s members, ThyraMIR is now covered for over 250 million lives nationwide, including through Medicare, National, and Regional health plans. This follows the Company’s recent announcement of its National contract with Aetna for its ThyGenX® and ThyraMIR products along with the approval by Cigna of ThyGenX.

The ThyGenX® – ThyraMIR® combination represents the only test in the market that includes the rule-in properties of next-generation sequencing of a patient’s DNA and RNA along with the rule-out capabilities of a micro-RNA classifier to provide physicians with clinically actionable test results. Based on current performance, approximately 90% of the Company’s ThyGenX cases are reflexed to ThyraMir for additional assessment.  The Company first launched ThyraMIR on April 15, 2015 making it available to Endocrinologists and Pathologists throughout the country.  Since then, the Company has conducted over 15,000 ThyraMIR tests for nearly 400 physicians and hospitals nationwide.

According to the American Cancer Society, thyroid cancer is the most rapidly increasing cancer in the U.S., tripling in the past three decades. Most physicians have traditionally recommended thyroid surgery where thyroid nodule biopsy results are indeterminate, not clearly benign or malignant, following traditional cytopathology review; however, 70%-80% of these surgical outcomes are ultimately benign.  Molecular testing using ThyGenX – ThyraMIR has been shown to reduce the rate of unnecessary surgeries in indeterminate cases.

Jack E. Stover, President and CEO of Interpace Diagnostics stated, “Oxford’s determination to cover ThyraMIR follows a steady stream of payers that have recognized the value that both of our Thyroid products play in identifying the appropriate patients for surgery.” “We are pleased that Oxford has joined the growing list of health plans that cover ThyraMIR and their  members in New York, New Jersey, and Connecticut will now have access to its benefits.”

About Thyroid Nodules, ThyGenX and ThyraMIR Testing

According to the American Thyroid Association, approximately 20% of the 525,000 thyroid fine needle aspirations (FNAs) performed on an annual basis in the U.S. are indeterminate for malignancy based on standard cytological evaluation, and thus are candidates for ThyGenX and ThyraMIR.

ThyGenX and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules.  The combination of both tests can improve risk stratification and surgical decision-making when standard cytopathology does not provide a clear diagnosis for the presence of cancer.

ThyGenX utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer. ThyraMIR is the first microRNA gene expression classifier.  MicroRNAs are small, non-coding RNAs that bind to messenger RNA and regulate expression of genes involved in human cancers, including every subtype of thyroid cancer. ThyraMIR measures the expression of 10 microRNAs.  ThyGenX and ThyraMIR are covered by both Medicare and Commercial insurers.

About Interpace Diagnostics Group, Inc.

Interpace Diagnostics is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The Company currently has three commercialized molecular tests; PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. Interpace Diagnostics’ mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to our future financial and operating performance. The company has attempted to identify forward looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.  These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to, our ability to adequately finance the business, our ability to restructure our liabilities and other obligations, the market’s acceptance of our molecular diagnostic tests; our ability to retain or secure reimbursement, our ability to secure additional business and generate higher profit margins through sales of our molecular diagnostic tests, in-licensing or other means, projections of future revenues, growth, gross profit and anticipated internal rate of return on investments and our ability to maintain our NASDAQ listing. Additionally, all forward-looking statements are subject to the risk factors detailed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (SEC), including without limitation, the Annual Report on Form 10-K filed with the SEC on March 31, 2017 and the amendment on Form 10-K/A filed on April 28, 2017, the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 filed with the SEC on May 12, 2017, and the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017 filed with the SEC on August 10, 2017. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

CONTACTS:

Interpace Diagnostics
Investor Relations:
Paul Kuntz – RedChip
paul@redchip.com

$DGLT Spike Leads to $NDAQ Info Request Halt

NEW YORK, Aug. 16, 2017 — The Nasdaq Stock Market^® (Nasdaq:NDAQ) announced that trading was halted today in Digiliti Money Group, Inc. (Nasdaq:DGLT) at 11:53:40 Eastern Time for “additional information requested” from the company at a last sale price of $1.0464.

Trading will remain halted until Digiliti Money Group, Inc. has fully satisfied Nasdaq’s request for additional information.

For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotes^SM on the Nasdaq^® Web site.

For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com.

NDAQO

Nasdaq Media Contact:
Emily Pan
emily.pan@nasdaq.com